Ultragenyx Pharmaceutical INC

Ultragenyx Pharmaceutical Inc. held its Annual Meeting on May 14, 2026, where stockholders approved the Third Amended and Restated 2023 Incentive Plan and ratified the appointment of Ernst & Young LLP.

Ultragenyx Pharmaceutical Inc. announced first quarter 2026 financial results, reporting $136 million in total revenue and reaffirming its full-year 2026 revenue guidance of $730 million to $760 million, while providing updates on key clinical programs.

The FDA has accepted the resubmitted Biologics License Application for UX111, setting a PDUFA action date of September 19, 2026.

Ultragenyx received FDA IND clearance for UX016, a sialic acid prodrug, and plans a patient-funded Phase 1/2 GNEM study in the second half of 2026.

Ultragenyx Pharmaceutical Inc. announced positive Phase 3 Enh3ance study results for its DTX301 gene therapy, demonstrating significant ammonia reduction in OTC deficiency patients.

The FDA has accepted Ultragenyx's Biologics License Application for DTX401 gene therapy for GSDIa, granting it Priority Review with an August 23, 2026 action date.

Ultragenyx Pharmaceutical Inc. reported increased product sales and royalty revenue for the nine months ended September 30, 2025, alongside significant clinical advancements and a new $400 million royalty sale agreement.

Ultragenyx Pharmaceutical Inc. reported increased revenues and reduced net loss in Q2 2025, driven by product sales growth and royalty revenue, while advancing its gene therapy and biologic pipeline despite a regulatory setback for UX111.

Ultragenyx Pharmaceutical Inc. announces its Q1 2025 financial results, showcasing revenue growth driven by product sales and providing updates on its clinical development programs, particularly in gene therapy and biologics.

Ultragenyx Pharmaceutical Inc. announced a significant increase in revenue for the third quarter of 2024, driven by strong product sales and advancements in its clinical development programs.

Ultragenyx Pharmaceutical Inc. reported increased revenue driven by product sales in Q2 2024, while also highlighting progress in its gene therapy clinical programs.

Ultragenyx Pharmaceutical Inc. reported a net loss of $170.7 million for the first quarter of 2024, with total revenues reaching $108.8 million, primarily driven by increased product sales.

Ultragenyx Pharmaceutical Inc. files its 10-K report, showcasing its commitment to rare disease treatments and pipeline advancements.

Ultragenyx Pharmaceutical Inc. grants restricted stock units to directors, outlining the terms and conditions under its 2023 Incentive Plan.

Karah Herdman Parschauer, EVP and Chief Legal Officer of Ultragenyx Pharmaceutical Inc., sold 1,900 shares of common stock on August 3, 2026 for $24.92 per share.

Howard Horn, Chief Financial Officer of Ultragenyx Pharmaceutical Inc., sold 4,696 shares of common stock on August 3, 2026 for $24.92 per share.

Howard Horn, Chief Financial Officer of Ultragenyx Pharmaceutical Inc., reported a transaction involving the purchase of common stock.

Director Corazon D. Sanders sold 2,000 shares of Ultragenyx Pharmaceutical Inc. common stock on June 15, 2026.

EVP and Chief Legal Officer Karah Parschauer sold 1,899 shares of Ultragenyx Pharmaceutical Inc. common stock.

Ultragenyx Pharmaceutical Inc. Chief Financial Officer Howard Horn sold 4,653 shares of common stock on June 1, 2026.

Ultragenyx Pharmaceuticals Inc. announces its 2025 Annual Meeting and provides details on proposals for stockholder voting, including director nominations, incentive plan approval, auditor ratification, and executive compensation.

Ultragenyx Pharmaceutical Inc. has released its proxy statement detailing proposals for the upcoming annual stockholders meeting, including director elections, incentive plan approval, auditor ratification, and executive compensation.

Ultragenyx Pharmaceutical Inc. has filed a definitive proxy statement with the SEC.

Ultragenyx Pharmaceutical Inc. has released its proxy statement detailing proposals for the upcoming annual stockholders meeting, including director elections, approval of an incentive plan, and executive compensation.

Vanguard Portfolio Management has reported a beneficial ownership of 6.95% in Ultragenyx Pharmaceutical Inc. as of June 30, 2026.

Vanguard Capital Management has disclosed a beneficial ownership of 5.13% of Ultragenyx Pharmaceutical Inc.'s common stock as of June 30, 2026.

State Street Corporation has reported beneficial ownership of 5.1% of Ultragenyx Pharmaceutical Inc.'s common stock as of March 31, 2026.

Vanguard Portfolio Management has reported a beneficial ownership of 5.5% in Ultragenyx Pharmaceutical Inc., holding over 5.4 million shares.

The Vanguard Group reported zero beneficial ownership in Ultragenyx Pharmaceutical Inc. common stock following an internal corporate realignment.

FMR LLC and Abigail P. Johnson have filed an amendment to their Schedule 13G, disclosing a 3.5% beneficial ownership stake in Ultragenyx Pharma Inc. as of December 31, 2025.